{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:44:49Z","timestamp":1772120689085,"version":"3.50.1"},"reference-count":64,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","theclinics.com","clinicalkey.com.au","clinicalkey.fr","liver.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.cld.2016.12.012","type":"journal-article","created":{"date-parts":[[2017,2,14]],"date-time":"2017-02-14T05:46:20Z","timestamp":1487051180000},"page":"421-434","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["The New Era of Hepatitis C"],"prefix":"10.1016","volume":"21","author":[{"given":"Ester Coelho","family":"Little","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Berenguer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cld.2016.12.012_bib1","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jhep.2006.05.001","article-title":"Report of the monothematic EASL conference on liver transplantation for viral hepatitis (Paris, France, January 12-14, 2006)","volume":"45","author":"Samuel","year":"2006","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2016.12.012_bib2","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1111\/j.1600-6143.2006.01362.x","article-title":"Interferon-based combination therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis","volume":"6","author":"Wang","year":"2006","journal-title":"Am J Transplant"},{"issue":"2","key":"10.1016\/j.cld.2016.12.012_bib3","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jhep.2008.05.002","article-title":"Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin","volume":"49","author":"Berenguer","year":"2008","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2016.12.012_bib4","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/j.1365-2893.2008.01019.x","article-title":"Pegylated interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta-analysis of prospective studies","volume":"15","author":"Xirouchakis","year":"2008","journal-title":"J\u00a0Viral Hepat"},{"issue":"6","key":"10.1016\/j.cld.2016.12.012_bib5","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.jhep.2011.12.031","article-title":"Comparison of two non-contemporaneous HCV-liver transplant cohorts: strategies to improve the efficacy of antiviral therapy","volume":"56","author":"Berenguer","year":"2012","journal-title":"J\u00a0Hepatol"},{"issue":"8","key":"10.1016\/j.cld.2016.12.012_bib6","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1111\/j.1600-6143.2005.00976.x","article-title":"Benefit of sustained virological response to combination therapy on graft survival of liver transplanted patients with recurrent chronic hepatitis C","volume":"5","author":"Bizollon","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cld.2016.12.012_bib7","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.jhep.2006.10.017","article-title":"Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation","volume":"46","author":"Picciotto","year":"2007","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2016.12.012_bib8","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/j.1600-6143.2007.02126.x","article-title":"Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation","volume":"8","author":"Berenguer","year":"2008","journal-title":"Am J Transplant"},{"issue":"1","key":"10.1016\/j.cld.2016.12.012_bib9","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/lt.23756","article-title":"Improved renal function in liver transplant recipients treated for hepatitis C virus with a sustained virological response and mild chronic kidney disease","volume":"20","author":"Bl\u00e9","year":"2014","journal-title":"Liver Transpl"},{"issue":"1","key":"10.1016\/j.cld.2016.12.012_bib10","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jhep.2010.11.012","article-title":"Immune-mediated complications of the graft in interferon-treated hepatitis C positive liver transplant recipients","volume":"55","author":"Selzner","year":"2011","journal-title":"J\u00a0Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2016.12.012_bib11","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1053\/j.gastro.2012.01.030","article-title":"Risk for immune-mediated graft dysfunction in liver transplant recipients with recurrent HCV infection treated with pegylated interferon","volume":"142","author":"Levitsky","year":"2012","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.cld.2016.12.012_bib12","first-page":"512","article-title":"Efficacy of telaprevir-based therapy in stable liver transplant patients with chronic genotype 1 hepatitis C","volume":"15","author":"Forns","year":"2016","journal-title":"Ann Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2016.12.012_bib13","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jhep.2013.08.018","article-title":"Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience","volume":"60","author":"Coilly","year":"2014","journal-title":"J\u00a0Hepatol"},{"issue":"8","key":"10.1016\/j.cld.2016.12.012_bib14","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1097\/TP.0000000000000629","article-title":"Telaprevir- and boceprevir-based triple therapy for hepatitis C in liver transplant recipients with advanced recurrent disease: a multicenter study","volume":"99","author":"Verna","year":"2015","journal-title":"Transplantation"},{"issue":"6 Spec No","key":"10.1016\/j.cld.2016.12.012_bib15","first-page":"SP212","article-title":"The wider public health value of HCV treatment accrued by liver transplant recipients","volume":"22","author":"Jena","year":"2016","journal-title":"Am J Manag Care"},{"issue":"5","key":"10.1016\/j.cld.2016.12.012_bib16","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1002\/hep.27681","article-title":"Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C following liver transplantation","volume":"61","author":"Forns","year":"2015","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.cld.2016.12.012_bib17","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1002\/hep.27770","article-title":"Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant","volume":"61","author":"Pungpapong","year":"2015","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.cld.2016.12.012_bib18","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1111\/liv.12856","article-title":"Sofosbuvir and simeprevir is effective for recurrent hepatitis C in liver transplant recipients","volume":"35","author":"Saab","year":"2015","journal-title":"Liver Int"},{"issue":"6","key":"10.1016\/j.cld.2016.12.012_bib19","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1002\/lt.24126","article-title":"Sofosbuvir and simeprevir for treatment of hepatitis C virus infection in liver transplant recipients","volume":"21","author":"Gutierrez","year":"2015","journal-title":"Liver Transpl"},{"issue":"1","key":"10.1016\/j.cld.2016.12.012_bib20","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/lt.24366","article-title":"Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: real-world experience from the hepatitis C therapeutic registry and research network","volume":"22","author":"Brown","year":"2016","journal-title":"Liver Transpl"},{"issue":"5","key":"10.1016\/j.cld.2016.12.012_bib21","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/lt.24422","article-title":"Simeprevir and sofosbuvir with or without ribavirin to treat recurrent genotype 1 hepatitis C virus infection after orthotopic liver transplantation","volume":"22","author":"Crittenden","year":"2016","journal-title":"Liver Transpl"},{"issue":"6","key":"10.1016\/j.cld.2016.12.012_bib22","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/ctr.12738","article-title":"Sofosbuvir and simeprevir without ribavirin effectively treat hepatitis C virus genotype 1 infection after liver transplantation in a two-center experience","volume":"30","author":"Jackson","year":"2016","journal-title":"Clin Transplant"},{"issue":"5","key":"10.1016\/j.cld.2016.12.012_bib23","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1097\/TP.0000000000001126","article-title":"Sofosbuvir-based antiviral therapy is highly effective in recurrent hepatitis c in liver transplant recipients: Canadian multicenter \u201creal-life\u201d experience","volume":"100","author":"Faisal","year":"2016","journal-title":"Transplantation"},{"issue":"3","key":"10.1016\/j.cld.2016.12.012_bib24","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/tid.12524","article-title":"Efficacy and safety of sofosbuvir\/ledipasvir for the treatment of patients with hepatitis C virus re-infection after liver transplantation","volume":"18","author":"Ciesek","year":"2016","journal-title":"Transpl Infect Dis"},{"issue":"1","key":"10.1016\/j.cld.2016.12.012_bib25","doi-asserted-by":"crossref","first-page":"e000066","DOI":"10.1136\/bmjgast-2015-000066","article-title":"Tolerability and effectiveness of sofosbuvir and simeprevir in the post-transplant setting: systematic review and meta-analysis","volume":"3","author":"Nguyen","year":"2016","journal-title":"BMJ Open Gastroenterol"},{"issue":"4","key":"10.1016\/j.cld.2016.12.012_bib26","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.jhep.2016.05.039","article-title":"Multicentre experience using daclatasvir and sofosbuvir to treat hepatitis C recurrence after liver transplantation - the CO23 ANRS CUPILT study","volume":"65","author":"Coilly","year":"2016","journal-title":"J\u00a0Hepatol"},{"issue":"10","key":"10.1016\/j.cld.2016.12.012_bib27","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1002\/lt.24505","article-title":"Sofosbuvir-based treatment of hepatitis C with severe fibrosis (METAVIR F3\/F4) after liver transplantation: results from the CO23 ANRS CUPILT study","volume":"22","author":"Dumortier","year":"2016","journal-title":"Liver Transpl"},{"issue":"4","key":"10.1016\/j.cld.2016.12.012_bib28","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1002\/lt.24416","article-title":"Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection","volume":"22","author":"Fontana","year":"2016","journal-title":"Liver Transpl"},{"issue":"11","key":"10.1016\/j.cld.2016.12.012_bib29","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/j.cgh.2015.05.030","article-title":"Efficacy of sofosbuvir and daclatasvir in patients with fibrosing cholestatic hepatitis C after liver transplantation","volume":"13","author":"Leroy","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2016.12.012_bib30","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1053\/j.gastro.2015.05.010","article-title":"Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease","volume":"149","author":"Charlton","year":"2015","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.cld.2016.12.012_bib31","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S1473-3099(16)00052-9","article-title":"Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial","volume":"16","author":"Manns","year":"2016","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"10.1016\/j.cld.2016.12.012_bib32","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/hep.28446","article-title":"Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence","volume":"63","author":"Poordad","year":"2016","journal-title":"Hepatology"},{"issue":"25","key":"10.1016\/j.cld.2016.12.012_bib33","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1056\/NEJMoa1408921","article-title":"An interferon-free antiviral regimen for HCV after liver transplantation","volume":"371","author":"Kwo","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.cld.2016.12.012_bib34","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1053\/j.gastro.2014.09.023","article-title":"Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study","volume":"148","author":"Curry","year":"2015","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.cld.2016.12.012_bib35","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/jvh.12534","article-title":"Treat chronic hepatitis C virus infection in decompensated cirrhosis - pre- or post-liver transplantation? The ironic conundrum in the era of effective and well-tolerated therapy","volume":"23","author":"Bunchorntavakul","year":"2016","journal-title":"J\u00a0Viral Hepat"},{"issue":"10","key":"10.1016\/j.cld.2016.12.012_bib36","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/ctr.12596","article-title":"A\u00a0pleasant dilemma to have: to treat the HCV patient on the waiting list or to treat post-liver transplantation?","volume":"29","author":"Barsa","year":"2015","journal-title":"Clin Transplant"},{"key":"10.1016\/j.cld.2016.12.012_bib37","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/lt.24051","article-title":"Patient with decompensated hepatitis C virus-related cirrhosis delisted for liver transplantation after successful sofosbuvir-based treatment","volume":"21","author":"Ruiz","year":"2015","journal-title":"Liver Transpl"},{"key":"10.1016\/j.cld.2016.12.012_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2016.05.010","article-title":"Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: a European study","author":"Belli","year":"2016","journal-title":"J\u00a0Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2016.12.012_bib39","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.jhep.2016.01.029","article-title":"Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis","volume":"64","author":"Foster","year":"2016","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2016.12.012_bib40","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jhep.2016.06.019","article-title":"Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis","volume":"65","author":"Cheung","year":"2016","journal-title":"J\u00a0Hepatol"},{"issue":"1 Suppl","key":"10.1016\/j.cld.2016.12.012_bib41","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1016\/j.jhep.2016.07.039","article-title":"Reversion of disease manifestations after HCV eradication","volume":"65","author":"Van Der Meer","year":"2016","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2016.12.012_bib42","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/liv.13193","article-title":"Impact of viral eradication with sofosbuvir-based therapy on the outcome of post-transplant hepatitis C with severe fibrosis","volume":"37","author":"Martini","year":"2016","journal-title":"Liver Int"},{"issue":"27","key":"10.1016\/j.cld.2016.12.012_bib43","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1056\/NEJMoa1512614","article-title":"Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis","volume":"373","author":"Curry","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cld.2016.12.012_bib44","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1111\/j.1600-6143.2011.03518.x","article-title":"Estimated risk of human immunodeficiency virus and hepatitis C virus infection among potential organ donors from 17 organ procurement organizations in the United States","volume":"11","author":"Ellingson","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cld.2016.12.012_bib45","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.jhep.2015.09.002","article-title":"Pros and cons: usage of organs from donors infected with hepatitis C virus \u2013 revision in the direct-acting antiviral era","volume":"64","author":"Coilly","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2016.12.012_bib46","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1053\/j.gastro.2016.04.003","article-title":"Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens","volume":"151","author":"Pawlotsky","year":"2016","journal-title":"Gastroenterology"},{"issue":"10003","key":"10.1016\/j.cld.2016.12.012_bib47","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/S0140-6736(15)00349-9","article-title":"Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study","volume":"386","author":"Roth","year":"2015","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.cld.2016.12.012_bib48","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s40264-016-0420-2","article-title":"Pharmacokinetics, efficacy, and safety of hepatitis C virus drugs in patients with liver and\/or renal impairment","volume":"39","author":"Smolders","year":"2016","journal-title":"Drug Saf"},{"issue":"1","key":"10.1016\/j.cld.2016.12.012_bib49","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jhep.2016.02.044","article-title":"Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C","volume":"65","author":"Desnoyer","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2016.12.012_bib50","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/hep.27922","article-title":"Safety and efficacy of simeprevir\/sofosbuvir in hepatitis C-infected patients with compensated and decompensated cirrhosis","volume":"62","author":"Saxena","year":"2015","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.cld.2016.12.012_bib51","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1002\/hep.27937","article-title":"Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis","volume":"62","author":"Aqel","year":"2015","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.cld.2016.12.012_bib52","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/lt.24324","article-title":"Safety and efficacy of simeprevir plus sofosbuvir with or without ribavirin in patients with decompensated genotype 1 hepatitis C cirrhosis","volume":"22","author":"Modi","year":"2016","journal-title":"Liver Transpl"},{"key":"10.1016\/j.cld.2016.12.012_bib53","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s10620-014-3422-x","article-title":"Hepatic decompensation likely attributable to simeprevir in patients with advanced cirrhosis","volume":"60","author":"Stine","year":"2015","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cld.2016.12.012_bib54","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2165\/00003088-200038010-00003","article-title":"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition","volume":"38","author":"Dresser","year":"2000","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.cld.2016.12.012_bib55","doi-asserted-by":"crossref","first-page":"600","DOI":"10.2174\/138945011795378504","article-title":"ABC multidrug transporters: target for modulation of drug pharmacokinetics and drug-drug interactions","volume":"12","author":"Marquez","year":"2011","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.cld.2016.12.012_bib56","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/hep.27920","article-title":"A\u00a0clinician's guide to drug-drug interactions with direct-acting antiviral agents for the treatment of hepatitis C viral infection","volume":"63","author":"Dick","year":"2016","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2016.12.012_bib57","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1053\/j.gastro.2014.10.001","article-title":"Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation","volume":"148","author":"Charlton","year":"2015","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.cld.2016.12.012_bib58","doi-asserted-by":"crossref","first-page":"32","DOI":"10.14218\/JCTH.2016.00001","article-title":"Curing hepatitis C in liver transplant recipients is associated with changes in immunosuppressant use","volume":"4","author":"Saab","year":"2016","journal-title":"J\u00a0Clin Transl Hepatol"},{"key":"10.1016\/j.cld.2016.12.012_bib59","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1053\/j.gastro.2015.07.063","article-title":"Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12\u00a0weeks in patients with HCV genotype 3 or 6 infection","volume":"146","author":"Gane","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2016.12.012_bib60","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1159\/000382075","article-title":"Daclatasvir, simeprevir and ribavirin as a promising interferon-free triple regimen for HCV recurrence after liver transplant","volume":"91","author":"Herzer","year":"2015","journal-title":"Digestion"},{"issue":"5","key":"10.1016\/j.cld.2016.12.012_bib61","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1002\/hep.28473","article-title":"Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: a randomized phase III study (ALLY-3+)","volume":"63","author":"Leroy","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2016.12.012_bib62","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1002\/lt.22175","article-title":"Post-liver transplant cholestatic hepatitis C: a systematic review of clinical and pathological findings and application of consensus criteria","volume":"16","author":"Narang","year":"2010","journal-title":"Liver Transpl"},{"key":"10.1016\/j.cld.2016.12.012_bib63","doi-asserted-by":"crossref","first-page":"5155","DOI":"10.3390\/v7092864","article-title":"Interferon-free hepatitis C treatment before and after liver transplantation: the role of HCV drug resistance","volume":"7","author":"Roche","year":"2015","journal-title":"Viruses"},{"issue":"S1","key":"10.1016\/j.cld.2016.12.012_bib64","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/lt.24520","article-title":"Last gasps of the HCV dragon: direct antiviral failures and HCV positive donors","volume":"22","author":"Berenguer","year":"2016","journal-title":"Liver Transpl"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326116301209?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326116301209?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,4]],"date-time":"2018-09-04T05:53:40Z","timestamp":1536040420000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326116301209"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":64,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S1089326116301209"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2016.12.012","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.737093676.793568730","asserted-by":"object"}]},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The New Era of Hepatitis C","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2016.12.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}